Date of publication: December 17, 2021

Decision of the Secretary of Health: Approved (18 January 2022)

Evidence Summary: Emtricitabine + Tenofovir Disoproxil Fumarate fixed-dose combination as Oral Pre-Exposure Prophylaxis (PrEP) to reduce the risk of sexually acquired HIV infection

Advisory for Appeals on Preliminary Recommendation: https://bit.ly/PrelimES-OralPrEP-Dec21

HTAC Recommendation Review: